

Table 3 Immediate and gradual effects of sanctions on diabetic, asthma, multiple sclerosis and cancer groups*

Diabetes group	Type of supply	Banking sanctions		CBI sanctions	
Sample name	(D, I, B)	Change in level (P)	Change in trend (P)	Change in level (P)	Change in trend (P)
Biguanides	B	2.09 (< 0.01)	0.04 (0.24)	0.64 (0.47)	-0.004 (0.95)
Sulfonylureas	B	3.77 (0.06)	-0.14 (0.16)	2.85 (0.2)	-0.37 (0.02)
Thiazolidinediones	D	0.05 (0.54)	-0.003 (0.44)	-0.06 (0.51)	-0.0009 (0.88)
Other blood glucose lowering drugs, excluding insulins	B	0.16 (0.08)	-0.007 (0.18)	0.21 (0.01)	-0.02 (< 0.01)
Insulins and analogues	B	0.15 (0.63)	0.02 (0.13)	0.26 (0.47)	0.001 (0.95)

Research article

Table 3 Immediate and gradual effects of sanctions on diabetic, asthma, multiple sclerosis and cancer groups* (concluded)

Asthma group	Type of supply	Banking sanctions		CBI sanctions	
Sample name	(D, I, B)	Change in level (P)	Change in trend (P)	Change in level (P)	Change in trend (P)
Selective β_2 -adrenoreceptor agonists	B	0.92 (0.64)	-0.36 (< 0.01)	-1.30 (0.56)	-0.38 (0.02)
Glucocorticoids	B	0.10 (0.52)	0.01 (0.25)	-0.03 (0.86)	0.009 (0.53)
Anticholinergics	B	Nonsignificant ITS model	Nonsignificant ITS model	Nonsignificant ITS model	Nonsignificant ITS model
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	B	3.19 (0.02)	-0.12 (0.11)	-1.54 (0.38)	-0.08 (0.54)
Adrenergics in combination with anticholinergics	B	Nonsignificant ITS model	Nonsignificant ITS model	0.16 (0.05)	-0.01 (0.04)
Multiple sclerosis group	Type of supply	Banking sanctions		CBI sanctions	
Sample name	(D, I, B)	Change in level (P)	Change in trend (P)	Change in level (P)	Change in trend (P)
Interferon β_1a	B	-0.03 (0.71)	-0.004 (0.39)	-0.06 (0.57)	-0.005 (0.48)
Interferon β_1b	I	0.01 (0.57)	-0.0009 (0.43)	0.01 (0.59)	-0.002 (0.19)
Cancer group	Type of supply	Banking sanctions		CBI sanctions	
Sample name	(D, I, B)	Change in level (P)	Change in trend (P)	Change in level (P)	Change in trend (P)
Interferon α_2b	D	-0.35 (0.03)	0.01 (0.19)	-0.43 (0.02)	0.01 (0.43)
Busereline acetate	B	-0.48 (0.29)	0.01 (0.44)	0.0002 (0.93)	0.0002 (0.35)
Cladribine	I	0.0001 (0.39)	-0.0000 (0.01)	-0.0001 (0.25)	-0.0000 (0.15)
Cytarabine	I	-0.71 (0.02)	-0.02 (0.09)	Nonsignificant ITS model	Nonsignificant ITS model
Dactinomycin	I	0.0000 (0.94)	-0.0000 (0.14)	1.42 (< 0.01)	-0.09 (< 0.01)
Docetaxel	I	0.07 (0.10)	-0.004 (0.06)	0.05 (0.24)	-0.01 (0.002)
Erlotinib	I	0.01 (0.42)	-0.006 (< 0.01)	-0.48 (0.15)	-0.09 (< 0.01)
Estramustine sodium phosphate	I	0.004 (0.93)	-0.008 (0.002)	-0.01 (0.82)	-0.009 (0.04)
Fludarabine phosphate	I	-0.005 (0.19)	-0.0003 (0.16)	-0.0003 (0.66)	-0.0003 (0.30)
Imatinib	B	-4.04 (0.39)	-0.17 (0.48)	6.32 (0.24)	-0.90 (0.05)
Capecitabine	B	1.30 (0.91)	-0.44 (0.49)	22.22 (0.10)	-2.30 (0.08)
Dauorubicin	I	Nonsignificant ITS model	Nonsignificant ITS model	Nonsignificant ITS model	Nonsignificant ITS model
Raloxifene	B	0.03 (0.01)	-0.003 (< 0.01)	Abnormality of residuals	Abnormality of residuals
Tamoxifen	D	-0.04 (0.16)	0.005 (< 0.01)	0.002 (0.93)	0.007 (< 0.01)

*Results of ITS analysis of impact of sanctions on diabetes, asthma, multiple sclerosis and selected cancer drugs.

B = both; CBI = Central Bank of Iran; D = domestic; I = imported; ITS = interrupted time series.